Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia
Sponsor: Biohaven Therapeutics Ltd.
Summary
The purpose of this study is to test the potential benefits of BHV-7000 in reducing chronic pain in participants with IEM with a previously demonstrated gain of function mutation in the SCN9A gene.
Official title: A Phase 1b, Double-Blind, Crossover Study of BHV-7000 in Patients With Inherited Erythromelalgia (IEM) With NaV1.7 Gain of Function Mutations
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
5
Start Date
2026-01-15
Completion Date
2026-11
Last Updated
2026-04-08
Healthy Volunteers
No
Conditions
Interventions
BHV-7000
Participants will take blinded investigational product (IP) orally once daily
Placebo
Matching placebo taken orally once daily
Locations (1)
Site-001
New Haven, Connecticut, United States